Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Indication: Sacituzumab govitecan for advanced urothelial cancer - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Indication: Sacituzumab govitecan for advanced urothelial cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Indication: Sacituzumab govitecan for advanced urothelial cancer

New Indication: Sacituzumab govitecan for advanced urothelial cancer
Study:
  • Open-label phase II trial (TROPHY-U-01). Cohort 1 results
  • Unresectable locally advanced or metastatic urothelial cancer progressed after CISplatin and checkpoint inhibitors
  • Sacituzumab govitecan 10 mg/kg on days 1,8 (21d) (N=113)
Efficacy:
  • CR: 6%, ORR: 27%
  • Median DoR: 5.9 mos
  • Median PFS: 5.4 mos [3.5-6.9 mos]
  • Median OS: 10.5 mos [8.2-12.3 mos]
Safety:
  • Grade >=3 AEs: neutropenia (35%), anemia (14%), febrile neutropenia (10%), diarrhea (10%)

Annals of Oncology (2020) 31 (suppl_4): S1142-S1215.

Loriot Y, et al. TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI)

https://doi.org/10.1016/annonc/annonc325

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More